Drug intelligence / Profile preview

tianlong tongluo

Development stage: Unknown
Lead developer: Mudanjiang Youbo Pharmaceutical
Administration: Oral

Overview

Tianlong Tongluo Capsule is a Traditional Chinese Medicine (TCM) developed by Mudanjiang Youbo Pharmaceutical for the treatment of ischemic stroke during the convalescent phase. It is specifically formulated to address 'wind-phlegm and blood stasis syndrome,' a common TCM diagnosis for post-stroke patients. The drug aims to improve neurological deficits and promote recovery by unblocking collaterals and improving blood circulation. It has been evaluated in Phase III clinical trials in China (e.g., CTR20132573) to assess its efficacy and safety in patients recovering from cerebral infarction.

Brand names: Tianlong Tongluo Capsule
Other names: 天龙通络胶囊

Targets

Fibrin (Factor Ia)

Beyond the preview

Go deeper on tianlong tongluo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tianlong tongluo.

Explore the full profile